Market research
COX.PA Nicox S.A
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 2.9
- Dividend yield
- 0.0%
- Beta
- 0.97
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0013018124
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- 2.9
- Dividend yield
- 0.0%
- Beta
- 0.97
About
About Nicox S.A
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the COX.PA discussion.
5 years, 5 months ago
Nicox S.A is currently in a long term downtrend where the price is trading 15.3% below its 200 day moving average.
From a valuation standpoint, the stock is 96.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.3.
Nicox S.A's total revenue sank by 0.0% to $632K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Nicox S.A gets an overall score of 2/5.